INTRODUCTION: We analyzed the ability of various patient- and treatment-related factors to predict radiation-induced esophagitis (RE) in patients with non-small cell lung cancer (NSCLC) treated with three-dimensional conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT), or proton beam therapy (PBT). METHODS AND MATERIALS: Patients were treated for NSCLC with 3D-CRT, IMRT, or PBT at MD Anderson from 2000 to 2008 and had full dose-volume histogram (DVH) data available. The endpoint was severe (grade≥3) RE. The Lyman-Kutcher-Burman (LKB) model was used to analyze RE as a function of the fractional esophageal DVH, with clinical variables included as dose-modifying factors. RESULTS: Overall, 652 patients were included: 405 patients were treated with 3D-CRT, 139 with IMRT, and 108 with PBT; corresponding rates of grade≥3 RE were 8%, 28%, and 6%, respectively, with a median time to onset of 42 days (range, 11-93 days). A fit of the fractional DVH LKB model demonstrated that the fractional effective dose was significantly different (P=.046) than 1 (fractional mean dose) indicating that high doses to small volumes are more predictive than mean esophageal dose. The model fit was better for 3D-CRT and PBT than for IMRT. Including receipt of concurrent chemotherapy as a dose-modifying factor significantly improved the LKB model (P=.005), and the model was further improved by including a variable representing treatment with >30 fractions. Examining individual types of chemotherapy agents revealed a trend toward receipt of concurrent taxanes and increased risk of RE (P=.105). CONCLUSIONS: Fractional dose (dose rate) and number of fractions (total dose) distinctly affect the risk of severe RE, estimated using the LKB model, and concurrent chemotherapy improves the model fit. This risk of severe RE is underestimated by this model in patients receiving IMRT.
INTRODUCTION: We analyzed the ability of various patient- and treatment-related factors to predict radiation-induced esophagitis (RE) in patients with non-small cell lung cancer (NSCLC) treated with three-dimensional conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT), or proton beam therapy (PBT). METHODS AND MATERIALS: Patients were treated for NSCLC with 3D-CRT, IMRT, or PBT at MD Anderson from 2000 to 2008 and had full dose-volume histogram (DVH) data available. The endpoint was severe (grade≥3) RE. The Lyman-Kutcher-Burman (LKB) model was used to analyze RE as a function of the fractional esophageal DVH, with clinical variables included as dose-modifying factors. RESULTS: Overall, 652 patients were included: 405 patients were treated with 3D-CRT, 139 with IMRT, and 108 with PBT; corresponding rates of grade≥3 RE were 8%, 28%, and 6%, respectively, with a median time to onset of 42 days (range, 11-93 days). A fit of the fractional DVH LKB model demonstrated that the fractional effective dose was significantly different (P=.046) than 1 (fractional mean dose) indicating that high doses to small volumes are more predictive than mean esophageal dose. The model fit was better for 3D-CRT and PBT than for IMRT. Including receipt of concurrent chemotherapy as a dose-modifying factor significantly improved the LKB model (P=.005), and the model was further improved by including a variable representing treatment with >30 fractions. Examining individual types of chemotherapy agents revealed a trend toward receipt of concurrent taxanes and increased risk of RE (P=.105). CONCLUSIONS: Fractional dose (dose rate) and number of fractions (total dose) distinctly affect the risk of severe RE, estimated using the LKB model, and concurrent chemotherapy improves the model fit. This risk of severe RE is underestimated by this model in patients receiving IMRT.
Authors: Jeffrey D Bradley; Jennifer Moughan; Mary V Graham; Roger Byhardt; Ramaswamy Govindan; Jack Fowler; James A Purdy; Jeff M Michalski; Elizabeth Gore; Hak Choy Journal: Int J Radiat Oncol Biol Phys Date: 2010-06-01 Impact factor: 7.038
Authors: R Mohan; G S Mageras; B Baldwin; L J Brewster; G J Kutcher; S Leibel; C M Burman; C C Ling; Z Fuks Journal: Med Phys Date: 1992 Jul-Aug Impact factor: 4.071
Authors: Maria Werner-Wasik; Ellen Yorke; Joseph Deasy; Jiho Nam; Lawrence B Marks Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: Lawrence B Marks; Ellen D Yorke; Andrew Jackson; Randall K Ten Haken; Louis S Constine; Avraham Eisbruch; Søren M Bentzen; Jiho Nam; Joseph O Deasy Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: Stephanie T H Peeters; Mischa S Hoogeman; Wilma D Heemsbergen; Augustinus A M Hart; Peter C M Koper; Joos V Lebesque Journal: Int J Radiat Oncol Biol Phys Date: 2006-06-06 Impact factor: 7.038
Authors: Xiong Wei; H Helen Liu; Susan L Tucker; Zhongxing Liao; Chaosu Hu; Radhe Mohan; James D Cox; Ritsuko Komaki Journal: Int J Radiat Oncol Biol Phys Date: 2006-07-12 Impact factor: 7.038
Authors: Steven E Schild; William L McGinnis; David Graham; Shauna Hillman; Tom R Fitch; Donald Northfelt; Yolanda I Garces; Homayoon Shahidi; Loren K Tschetter; Paul L Schaefer; Alex Adjei; James Jett Journal: Int J Radiat Oncol Biol Phys Date: 2006-05-26 Impact factor: 7.038
Authors: Hendrik P Bijl; Peter van Luijk; Rob P Coppes; Jacobus M Schippers; Antonius W T Konings; Albert J van der Kogel Journal: Int J Radiat Oncol Biol Phys Date: 2006-03-15 Impact factor: 7.038
Authors: Xin Shelley Wang; Qiuling Shi; Loretta A Williams; Ritsuko Komaki; Daniel R Gomez; Steven H Lin; Joe Y Chang; Michael S O'Reilly; Raza H Bokhari; James D Cox; Radhe Mohan; Charles S Cleeland; Zhongxing Liao Journal: J Pain Symptom Manage Date: 2016-02-16 Impact factor: 3.612
Authors: S E Combs; D Habermehl; K Kessel; F Bergmann; J Werner; I Brecht; P Schirmacher; D Jäger; M W Büchler; J Debus Journal: Strahlenther Onkol Date: 2013-07-31 Impact factor: 3.621
Authors: Joshua S Niedzielski; Jinzhong Yang; Francesco Stingo; Mary K Martel; Radhe Mohan; Daniel R Gomez; Tina M Briere; Zhongxing Liao; Laurence E Court Journal: Int J Radiat Oncol Biol Phys Date: 2015-10-14 Impact factor: 7.038
Authors: José Marcio Luna; Hann-Hsiang Chao; Russel T Shinohara; Lyle H Ungar; Keith A Cengel; Daniel A Pryma; Chidambaram Chinniah; Abigail T Berman; Sharyn I Katz; Despina Kontos; Charles B Simone; Eric S Diffenderfer Journal: Clin Transl Radiat Oncol Date: 2020-03-24